Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity
Hepatocellular carcinoma (HCC) accounts for most of primary liver cancer, of which five-year survival rate remains low and chemoprevention has become a strategy to reduce disease burden of HCC. We aim to explore the in vivo chemopreventive effect of an organoselenium-containing compound butaselen (B...
Main Authors: | Xiaoqing Zheng, Weiwei Ma, Ruoxuan Sun, Hanwei Yin, Fei Lin, Yuxi Liu, Wei Xu, Huihui Zeng |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2018-04-01
|
Series: | Redox Biology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231717307036 |
Similar Items
-
Corrigendum to ‘Butaselen prevents hepatocarcinogenesis and progression through inhibiting thioredoxin reductase activity’ [Redox Biol. 14 (2018) 237–249]
by: Xiaoqing Zheng, et al.
Published: (2020-05-01) -
Therapeutic Effects of an Inhibitor of Thioredoxin Reductase on Liver Fibrosis by Inhibiting the Transforming Growth Factor-β1/Smads Pathway
by: Wenxuan Jiao, et al.
Published: (2021-09-01) -
Clinical application of thioredoxin reductase as a novel biomarker in liver cancer
by: Xuping Wu, et al.
Published: (2021-03-01) -
Inhibition and crosslinking of the selenoprotein thioredoxin reductase-1 by p-benzoquinone
by: Nan Shu, et al.
Published: (2020-01-01) -
Thioredoxin and Its Reductase Are Present on Synaptic Vesicles, and Their Inhibition Prevents the Paralysis Induced by Botulinum Neurotoxins
by: Marco Pirazzini, et al.
Published: (2014-09-01)